A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

NCT07241416 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Interventions

DRUG: Rezvilutamide Tablets
DRUG: Enzalutamide Soft Capsules

Sponsor

Jiangsu HengRui Medicine Co., Ltd.